Navarro NM, Euan BOG, Bolado ME, Moreno IGM, Castillón CLG, Robles ZRE

Language: Spanish
References: 18
Page: 40-44
PDF size: 177.75 Kb.

ABSTRACT

Several studies have shown a high prevalence of multidrug resistance to antibiotics in community-acquired uropathogenic Escherichia coli. The prevalence of resistant isolates is variable in different regions, it is important to conduct surveillance studies to select empirical treatment.
Material and Method. We conducted a retrospective study to assess antibiotic resistance in a total 120 isolates of community-acquired uropathogenic Escherichia coli recovered through the years 2013 and 2014 in a first-level care clinic in Hermosillo, Sonora, Mexico. Identification tests, antibiotics susceptibility assays and detection of extended-spectrum β-lactamases (ESBL) production were performed using MicroScan (Siemens) system.
Results. The highest antibiotic resistance rates, were detected to fluoroquinolones (58.3%), trimethoprim-sulfamethoxazole (44.2%) and cephalothin (41.7%). Thirty-five percent of the isolates were ESBL producers. In contrast, the lowest resistance rates were observed against nitrofurantoin (3.3%). The most frequent co-resistant phenotype observed was to fluoroquinolones and third-generation cephalosporins (33.3%), followed by fluoroquinolones and trimethoprim-sulfamethoxazole (28.3%).
Conclusions. A high rate of resistance was detected, except for nitrofurantoin, against antibiotics used for empirical treatment for community-acquired urinary tract infections. The results obtained from this study are cause for epidemiological concern, and a strict follow-up in the coming years is required.

REFERENCES

1. Chávez-Valencia, V., Gallegos-Nava, S. y Arce-Salinas, A., “Patrones de resistencia antimicrobiana y etiología en infecciones urinarias no complicadas”, Gac Méd Méx, 2010, 146: 269-273.

2. McIsaac, W.J., Moineddin, R., Meanye, C. y Mazzulli, T., “Antibiotic-resistant Escherichia coli in women with acute cistitis in Canada”, Can J Infect Dis Med Microbiol, 2013, 24: 143-149.

3. Cullen, I.V., Manecksha, R.P., McCullagh, E., Ahmad, S., O’Kelly, F., Flynn, R.J., McDermott, T., Murphy, P., Grainger, R., Fennell, J.P. y Thornhill, J.A., “The changing pattern of antimicrobial resistance within 42 033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999- 2009”, bjui, 2011, 109: 1198-1206.

4. Molina-López, J., Aparicio-Ozores, G., Ribas-Aparicio, R.M., Gavilanes-Parra, S., Chávez-Berrocal, E., Hernández- Castro, R. y Manjarrez-Hernández, H.A., “Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City”, J Infect Dev Ctries, 2011, 5: 840-849.

5. Lerma, M., Cebrián, L., Giménez, M.J., Coronel, P., Gimeno, M., Aguilar, L. y García de Lomas, J., “β-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes”, Rev Esp Quimioter, 2008, 21: 149-152.

6. Kudinha, T., Johnson, J.R., Andrew, S.D., Kong, F., Anderson, P. y Gilvert, G.L., “Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive age women”, J Clin Microbiol, 2013, 51: 3270-3276.

7. Nicolle, L.E., “Antimicrobial resistance in community-acquired Escherichia coli isolated from urinary infection: good news or bad?”, Can J Infect Dis Med Microbiol, 2013, 24: 123-124.

8. Colgan, R. y Williams, M., “Diagnosis and treatment of acute uncomplicated cistitis”, American Fam Phys, 2011, 84: 771-776.

9. Kalpana, G., Hooton, T.M., Naber, K.G. et al., “International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases”, Clin Infect Dis, 2011, 52: e103-e120.

10. Navarro-Navarro, M., Robles-Zepeda, R.E., Garibay-Escobar, A., Ruiz-Bustos, E., Escobar-López, R. y Velázquez- Contreras, C.A., “Alta prevalencia de resistencia a los antibióticos en Escherichia coli uropatógena comunitaria, detectada en hospitales de Hermosillo, Sonora”, Enf Inf Microb, 2013, 33: 66-70.

11. Gupta, K., Hooton, T.M., Naver, K.G., Björn, W. et al., “International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases”, Clin Infect Dis, 2011, 52: e103-e120.

12. Marchisio, M., Porto, A., Joris, R., Rico, M., Abroi, M.R. y Di Conza, J., “Susceptibility to beta-lactams and quinolones of Enterobacteriaceae isolated from urinary tract infections in outpatients”, Braz J Microbiol, 2015, 46: 1155-1159.

13. Talan, D.A., Takhar, S.S., Krishnadasan, A. et al., “Fluroquinolone- resistant and extended-spectrum beta-lactamase producing Escherichia coli infections in patiens with pyelonephritis, United States”, Emerg Inf Dis, 2016, 22: 1594-1603.

14. Betitra, Y., Vinuesa, T., Viñas, M. y Abdelaziz, T., “Determinants of quinolone resistance in Escherichia coli causing community-acquired urinary tract infection in Bejaia, Algeria”, Asian Pacific J Trop Med, 2014, 7: 462-467.

15. Ben Zakour, N.L., Alsheikh-Hussain, A.S., Ashcroft, M.M., Khanh Nhu, N.T., Roberts, L.W., Stanton-Cook, M., Schembri, M.A. y Beatson, S.A., “Sequential acquisition of virulence and fluoroquinolone resistance has shaped the evolution of Escherichia coli ST131”, MBio, 2016, 26 (7): e00347-16.

16. Petty, N.K., Ben Zakour, N.L., Stanton-Cook, M. et al., “Global dissemination of a multidrug resistant Escherichia coli clone”, pnas, 2014, 111: 5694-5699.

17. Johnson, J.R., Johnston, B., Clabots, C., Kuskowski, M.A. y Castanheira, M., “Escherichia coli sequence type st13 as the major cause of serious multridrug-resistent E. coli infections in the United States”, Clin Infect Dis, 2010, 51: 286-294.

18. Manikandan, S., Ganesapandian, S., Singh, M. y Kumaraguru, A.K., “Emerging of multidrug resistance human pathogens from urinary tract infections”, Curr Res Bacteriol, 2011, 4: 9-15.